Degludec outperforms glargine in reducing nocturnal hypoglycemia

05/21/2013 | InternalMedicineNews.com (free registration)

Type 1 diabetes patients who took high doses of insulin degludec once daily had lower rates of nocturnal hypoglycemia during the full trial and maintenance periods than those who took insulin glargine, a meta-analysis indicated. The findings were presented at the American Association of Clinical Endocrinologists annual meeting.

View Full Article in:

InternalMedicineNews.com (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Actuary
Meridian Health Plan
Detroit, MI
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC